Evidence map›Paper›PMID 30189190›Full record

ReviewChest2018

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.

Karthik Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Danoff

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chest, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04036721 (Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease), which is not on this map. Cited by 258 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
258citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04036721 phase4suspendednot on this mapstarted 2019, after this paper: background citation

Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies

TypeinterventionalSponsorNational Institute for Tuberculosis and Lung Diseases, PolandRan2019 to 2026Enrolled85ConditionsLung Neoplasm Malignant, Interstitial Lung DiseaseArmsProlonged glucocorticosteroid (prednisone) regimen, Short glucocorticosteroid (prednisone) regimen
3 · Its place in the literature

Who cites it

258 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Journal of thoracic disease · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

198 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karthik SureshDivision of Pulmonary Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: ksuresh2@jhmi.edu.
Jarushka NaidooDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Cheng Ting LinDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD.
Sonye DanoffDivision of Pulmonary Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

Funding

ROS-induced endothelial dysfunction in pulmonary arterial hypertensionK08HL132055 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SURESH, KARTHIK · 2017 to 2021
$828k
NHLBI NIH HHS K08 HL132055
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike traditional chemotherapeutic agents, ICIs work by boosting the body's natural tumor killing response. However, this unique mechanism of action has also led to the recognition of class-specific side effects. Labeled immune-related adverse events, these toxicities can affect multiple organ systems including the lungs. Immune-mediated lung injury because of ICI use, termed checkpoint inhibitor pneumonitis (CIP), occurs in about 3% to 5% of patients receiving ICIs; however, the real-world incidence of this entity may be higher, especially now that ICIs are being used in nonclinical trial settings. In this review, we briefly introduce the biology of ICIs and the indications for ICI use in NSCLC and then discuss the epidemiology and clinical and radiologic manifestations of CIP. Next, we discuss management strategies for CIP, including the current consensus on management of steroid-refractory CIP. Given the nascent nature of this field, we highlight areas of uncertainty and emerging research questions in the burgeoning field of checkpoint inhibitor pulmonary toxicity.

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsPneumoniaHumansPatient Care ManagementRisk AdjustmentimmunotherapyNSCLCpneumonitis

Identifiers

PMID30189190
PMCPMC6335259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.